Objectives: HIV-2-infected individuals usually initiate antiretroviral therapy (ART) at an advanced age compared with HIV-1 patients, with a potential impact on treatment outcomes. This study aimed to investigate the effect of sex and age on mortality and loss to follow-up (LTFU) among HIV-2-infected individuals initiating ART.
Introduction
HIV-2 infection is mainly localized in West Africa, with a limited spread to other parts of the world [1] . People infected with HIV-2 experience a longer asymptomatic phase, a slower immunologic progression, and a lower virologic replication compared with those infected with HIV-1 [2] [3] [4] . Because of the intrinsic resistance of HIV-2 to nonnucleoside reverse transcriptase inhibitors (NNRTIs), treatment options in resource-limited settings for HIV-2-infected individuals are limited and this may affect treatment sequencing in case of failure and longterm outcomes of these patients [5] [6] [7] .
Similar to HIV-1 infection, more women than men are infected with HIV-2 [8] [9] [10] , with a significantly advanced age at diagnosis and antiretroviral therapy (ART) initiation among HIV-2-infected individuals compared with HIV-1 [11] . In resource-limited settings, higher mortality [12] [13] [14] and loss to follow-up (LTFU) rates have been reported in men than in women among HIV-1-infected individuals [9, [15] [16] [17] , as well as an association between LTFU and mortality [18] . Many possible explanations such as baseline characteristics [19, 20] , late presentation (79% of HIV-1-infected individuals initiating ART with CD4 þ cell count <200/ml), high viral load (>5 log), and suboptimal immunologic response [14, 21] have been suggested, but the underlying causes of these findings remain poorly understood.
The relationship between ARToutcomes and sex, as well as age have been well described among HIV-1-infected individuals in resource-limited settings, but very poorly studied in HIV-2-infected individuals because of lack of power related to a limited sample size of HIV-2 cohorts in each country. Considering the different disease pattern of HIV-2 infection compared with HIV-1, we evaluated mortality, LTFU, and associated determinants among ART-receiving HIV-2-infected individuals.
Methods
Study design, site, and population This analysis was conducted among patients in the International Epidemiological Databases to Evaluate AIDS (IeDEA)-West Africa HIV-2 cohort that has been previously described [22] . This dynamic cohort is currently made up of 5193 HIV-2 and HIV-1/HIV-2 dually reactive individuals followed up in 15 West African clinics, in seven countries (Benin, Burkina Faso, Cote d'Ivoire, Guinea-Bissau, Mali, Senegal, and Togo). Patients were included in this cohort based on the results of the HIV testing performed according to the national algorithms of each participating country. The HIV diagnosis and the initial classification of patients of the IeDEA-West Africa HIV-2 cohort have been described elsewhere [23] . The study population considered for this analysis was HIV-2-monoinfected patients only, aged 16 years old and above, initiating ART between February 1997 and September 2014, and followed up till 15 May 2015. The routine care of patients (ART distribution and biological testing) follows the national HIV treatment guidelines of each country, most of them recommending ART initiation below 350 CD4 þ cells/ml [22] .
Variables and definition
Baseline characteristics used in this analysis refer to measurements recorded immediately before ART initiation for specific variables such as demographics (age, sex), disease progression (CD4 þ cell count, WHO clinical stage) as well as clinical and biological parameters of patients [weight, haemoglobin (Hb)]. The following variables were transformed into categorical ones: age (16-39; 40-49 ; !50 years), initial CD4 þ cell count (0-99; 100-199; 200-349; !350 cells/ml), Hb at enrolment (<7.5; 7.5-9.9; 10-12; >12 g/dl), BMI at enrolment (<18; 18-25; >25 kg/m 2 ), and WHO clinical stage (I-II and III-IV).
Outcomes and definition
The primary outcome was all-cause mortality based on the living status reported at the closing date (15 May 2015) of the cohort's database for this analysis, after an active search by home visit, phone tracking of patients, or calling a close relative of the participant when the contact details were available.
Secondary outcome was LTFU, defined as a patient who was neither reported dead nor transferred out, and whose date of last visit was more than 6 months prior to the closing date of the cohort's database for this analysis (15 May 2015) . Patients returning into care before the closing date of the cohort were not LTFU even when they had missed more than three consecutive visits (HIV care visits are usually programmed every 3 months).
Data collection and management
A dedicated case report file (CRF) was used to collect enrolment and follow-up data for all HIV-2-infected individuals included in the cohort. Follow-up characteristics (death or LTFU) were checked by social workers and notified to doctors who reported in the CRF. Data of each CRF were recorded in a local database built with Microsoft Access software (Microsoft Corporation, Redmond, Washington, USA).
Statistical analysis
Baseline characteristics and summary outcomes were compared between men and women and between age groups. Differences between proportions and medians were tested with Pearson's x 2 test or Mann-Whitney test. Probability and median survival time from the date of ART initiation to death or LTFU was estimated by Kaplan-Meier methods. Cox proportional hazards regression models were used to assess crude and adjusted hazard ratios (HRs) between baseline characteristics and outcomes (death or LTFU), over the first 24 months after ART initiation. For patients neither dead nor LTFU, the closing date of the follow-up was 15 May 2015. For patients who experienced death or LTFU during the observation period, the censor date was the date of the first event, meaning date of death for dead patients and date of the last visit for patients LTFU). Interactions between adjustment factors and sex or age were tested and possible confounders were checked. Univariable Cox models were performed to assess covariate effect; manual backwards selection method was performed to select significant covariates in a multivariable Cox model. The level of significance for all analyses was a two-sided P value of less than 0.05. All statistical analyses were performed with the statistical software package, Stata 11.0 software (Stata Corp, College Station, Texas, USA).
Ethics
The IeDEA-West Africa HIV-2 cohort's protocol has been approved by the national ethic committee of each participating country. All the patients gave their written consent or fingerprint if illiterate before being included in the cohort. , log-rank test P ¼ 0.001] (Fig. 1a ). Mortality was also associated with age at ART initiation (log-rang test, P value ¼ 0.026). Figure 1b shows a higher probability of death among people initiating ART at 50 years or older compared with those initiating ART at a younger age (Fig. 1b ). ART regimen after adjusting on other baseline characteristics. Fig. 2a and 2b) . 
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Discussion
This study reports on HIV-2 ART-programme outcomes according to sex and age in a large West African multicountry cohort. The overall number of deaths was 221 (12.1%), for a global mortality rate of 3.7/100 pyo [95% CI (3.2-4.2)]. Over the first 24 months after ART initiation, the mortality rate was estimated to be 5.2/100 pyo with a death probability of 7.7%. Men had higher mortality rate than women, especially those initiating ART at an advanced age. Approximately, one-quarter of the patients were LTFU after 24 months on ART, and the retention rate was only 66%. Male sex, advanced age at ART initiation, ART initiation after 2007, low initial Hb level, and low BMI were associated with mortality and with LTFU at 24 months, whereas low initial CD4 þ cell count was only associated with mortality.
In our study, among ART-receiving HIV-2-infected individuals, the crude mortality rate was high, around 12% after a median follow-up duration of 28.8 months and one-third of deaths occurred during the first 6 months after starting ART. Thus, despite the differences in disease progression between HIV-1 and HIV-2, the estimates of mortality in ART-receiving HIV-2-infected individuals appear to be comparable with what is seen in HIV-1 infection in sub-Saharan Africa (SSA) [24] [25] [26] [27] . Like in HIV-1 infection, late presentation (20% of patients with CD4 þ cell count <100 cells/ml) could explain this high mortality rate in HIV-2-infected individuals receiving ART. The suboptimal immune recovery (only þ100 CD4 þ cells/ml after the first 24 months of ART), which is $two times lower in our cohort than that observed in HIV-1-infected individuals over the same period [26] , may also play a role in this high mortality rate. In addition, men were more likely to die than women in our cohort, as has been reported in ARTreceiving HIV-1-infected individuals [10, 13, 14] . Baseline clinical and laboratory characteristics have been identified as possible factors explaining this sex difference in mortality in HIV-1-infected individuals [12, [18] [19] [20] 28] . Similar associated factors were found in our study, especially the CD4 þ cell counts that were lower in men than in women at ART initiation, indicating higher rates of late presentation among men. Age is another cofactor frequently cited to explain the difference in mortality among ART-receiving men and women. Many surveys identified the older age of men compared with women at ART initiation, as a reason for sex difference in mortality [9, 13, 14, 29] . In our cohort, more men than women initiated ART after the age of 50 and this age difference could also partly explain the difference in mortality between men and women. Individuals initiating ART after 2007 in our cohort had higher mortality than those initiating ART earlier. This result contrast with findings from other HIV-1 studies, reporting a tremendous decline in mortality and LTFU with the scaling-up of ART programmes [12, 28, 29] . One possible explanation for our finding could be the potential for the lower likelihood of being captured in programmatic databases for patients who started ART prior to 2007, and died or who were lost to follow-up soon after entering care, compared with patients who survived.
Our study found a tremendous increase of LTFU in HIV-2-infected adults at 6, 12, and 24 months after ART initiation. Many other surveys from SSA reported similar or higher rates of LTFU among HIV-1-infected individuals receiving ART [14, 17, 18, 29] . In these studies, LTFU was associated with age at ART initiation, male sex, low BMI, low Hb level, and sometimes with low CD4 þ cell count at ART initiation [14, 17, 18, 29] . All these factors are also known to be associated with mortality in HIV-1-infected individuals, and many studies report that 30-40% of patients LTFU are misclassified deaths [13, 18, 30] . Our analysis retrieved the same factors associated with LTFU among HIV-2infected individuals receiving ART, and we speculate that a considerable number of patients LTFU in our cohort may be misclassified deaths.
Retention in care is a major outcome to assess success of ART delivery programmes as it takes into accounts both deaths and LTFU. A 2007 meta-analysis among HIV-1infected patients on ART in SSA reported retention of 75.0% at 12 months and 61.6% at 24 months [31] . More recently, a 2012 systematic review on retention and LTFU among HIV-infected patient in SSA reported a retention rate of 65% [95% CI (58-73)] among ART-receiving individuals after 3 years of follow-up [32] . The results in HIV-2-infected patients are similar with a retention rate of 77.9% at 12 months and 66% at 24 months and lower retention among men. This low retention in care suggests high ART discontinuation and the possible development of ART resistance. ART resistance is of concern, especially for HIV-2-infected individuals in SSA, who initiate ARTwith a protease inhibitor-based regimen, but have limited or no access to effective second-line ART [33] [34] [35] .
Some limitations should be considered when interpreting our study results. First, we used data from routine HIV care that usually included significant levels of missing data even after data queries. Second, the death assessment was limited to hospital reports or patient's family notification, mainly because of the weakness of the national death registries from contributing IeDEA-West Africa countries. Furthermore, HIV-2 viral load data were not routinely available to assess whether those who died or were LTFU had virologic failure.
This study underscores the fact that like in HIV-1 cohorts, HIV-2 ART-receiving men are more likely to die and have a lower retention rate than women. There is an urgent need to improve HIV-2 programmatic outcomes, reduce mortality and LTFU, educate clinicians and programmes about low retention rates, and explore interventions to improve the cascade of care for both men and women infected with HIV-2.
